-
1.发明申请CHEMOKINE DERIVED PEPTIDES AND USES FOR CHRONIC WOUND AND ANGIOGENESIS INHIBITION TREATMENTS 有权化学发光肽和用于慢性创伤和血管生成抑制治疗的用途公开(公告)号：US20130053319A1
公开(公告)日：2013-02-28
申请号：US13219375
申请日：2011-08-26
CPC分类号： A61K38/195 , A61K47/551 , C07K14/522
摘要： Disclosed are peptides having activity against receptor CXCR3 are disclosed that exhibit activity in preventing the formation of new vessels and activity in mediating the dissociation of newly-formed vessels and resolving of wounds in the later stages of wound healing. Preferred peptides are derived from the α-helix portion IP-10 (CXCL10) or from IP-9 (CXCL11), are nontoxic, and smaller than naturally occurring peptides, making them useful in therapies against diseases or disease states marked by unwanted angiogenesis, including tumorogenic diseases such as cancers, and in healing of chronic wounds.
摘要翻译： 公开了具有针对受体CXCR3的活性的肽，其表现出在预防新血管形成中的活性和介导新形成的血管解离和在伤口愈合后期分解伤口的活性。 衍生自α-螺旋部分IP-10（CXCL10）或来自IP-9（CXCL11）的优选肽是无毒的且小于天然存在的肽，使得它们可用于治疗由不想要的血管发生标记的疾病或疾病状态， 包括肿瘤发生疾病如癌症，以及慢性伤口愈合。
-
2.发明授权Chemokine derived peptides that bind with chemokine receptor CXCR3 and uses for chronic wound and angiogenesis inhibition treatments 有权与趋化因子受体CXCR3结合并用于慢性伤口和血管发生抑制治疗的趋化因子衍生肽公开(公告)号：US08734775B2
公开(公告)日：2014-05-27
申请号：US13219375
申请日：2011-08-26
IPC分类号： A61K38/19 , A61K45/00 , C07K14/435
CPC分类号： A61K38/195 , A61K47/551 , C07K14/522
摘要： Disclosed are peptides having activity against receptor CXCR3 are disclosed that exhibit activity in preventing the formation of new vessels and activity in mediating the dissociation of newly-formed vessels and resolving of wounds in the later stages of wound healing. Preferred peptides are derived from the α-helix portion IP-10 (CXCL10) or from IP-9 (CXCL11), are nontoxic, and smaller than naturally occurring peptides, making them useful in therapies against diseases or disease states marked by unwanted angiogenesis, including tumorogenic diseases such as cancers, and in healing of chronic wounds.
摘要翻译： 公开了具有针对受体CXCR3的活性的肽，其表现出在预防新血管形成中的活性和介导新形成的血管解离和在伤口愈合后期分解伤口的活性。 衍生自α-螺旋部分IP-10（CXCL10）或来自IP-9（CXCL11）的优选肽是无毒的且小于天然存在的肽，使得它们可用于治疗由不想要的血管发生标记的疾病或疾病状态， 包括肿瘤发生疾病如癌症，以及慢性伤口愈合。
-
3.发明授权Lytic peptides having anti-proliferative activity against prostate cancer cells 有权对前列腺癌细胞具有抗增殖活性的裂解肽公开(公告)号：US08461118B2
公开(公告)日：2013-06-11
申请号：US13178042
申请日：2011-07-07
申请人： Clayton Yates , Jesse Jaynes , Timothy Turner
发明人： Clayton Yates , Jesse Jaynes , Timothy Turner
CPC分类号： C07K14/4723 , A61K38/00 , C07K7/23 , C07K2319/33
摘要： Lytic peptides, including fusion peptides of lytic peptides conjugated with luteinizing hormone-releasing hormone or modified versions thereof to target luteinizing hormone-releasing hormone receptors, are disclosed. The lytic peptides show anti-proliferative activity against human prostate cancer cell lines, but are nontoxic to normal primary human prostate epithelial cells or to bone marrow stromal cells in co-culture. The lytic peptides have specificity for and anti-proliferative activity against prostate cancer tumor cells, and low toxicity for normal prostate cells, making the peptides useful in therapies for prostate cancer.
摘要翻译： 公开了Lytic肽，包括与促黄体生成激素释放激素结合的裂解肽的融合肽或其修饰形式靶向促黄体生成激素释放激素受体。 裂解肽显示对人前列腺癌细胞系的抗增殖活性，但对于正常的原代人前列腺上皮细胞或共培养中的骨髓基质细胞无毒性。 溶解肽对前列腺癌肿瘤细胞具有特异性和抗增殖活性，对正常前列腺细胞具有低毒性，使得该肽可用于前列腺癌的治疗。
-
公开(公告)号：US06235729B1
公开(公告)日：2001-05-22
申请号：US08824149
申请日：1997-03-25
申请人： Philip Chen , Timothy Turner , Alan Wells
发明人： Philip Chen , Timothy Turner , Alan Wells
IPC分类号： A61K3158
CPC分类号： A61K31/685 , A61K31/15 , A61K31/27 , A61K31/58
摘要： The present invention provides a method of inhibiting tumor progression in an individual in need of such treatment, comprising the step of administering to said individual a pharmacologically effective dose of a phospholipase C inhibitor. Also provided is a method of inhibiting metastasis in an individual in need of such treatment, comprising the step of administering to said individual a pharmacologically effective dose of a phospholipase C inhibitor. Further provided are pharmaceutical compositions, comprising a phospholipase C inhibitor of tumor invasiveness and metastasis and a pharmaceutically acceptable carrier and a pharmaceutical composition, comprising a phospholipase C inhibitor of tumor invasiveness and metastasis, a antineoplastic agent and a pharmaceutically acceptable carrier.
摘要翻译： 本发明提供抑制需要这种治疗的个体中肿瘤进展的方法，包括向所述个体施用药理学有效剂量的磷脂酶C抑制剂的步骤。 还提供了在需要这种治疗的个体中抑制转移的方法，包括向所述个体施用药理学有效剂量的磷脂酶C抑制剂的步骤。 还提供了包含肿瘤侵袭和转移的磷脂酶C抑制剂和药学上可接受的载体和药物组合物的药物组合物，其包含肿瘤侵袭和转移的磷脂酶C抑制剂，抗肿瘤剂和药学上可接受的载体。
-
公开(公告)号：US08328492B2
公开(公告)日：2012-12-11
申请号：US11929072
申请日：2007-10-30
IPC分类号： B21D51/44
CPC分类号： B21D51/383 , B65D17/08 , B65D17/4012 , B65D17/502 , B65D2517/0007 , B65D2517/0011 , B65D2517/0061 , B65D2517/0076 , B65D2517/0079 , B65D2517/0082
摘要： A can end member has a center panel, a circumferential chuck wall, and a transition wall. The center panel is centered about a longitudinal axis and has a peripheral edge. The center panel also has a step portion located radially outwardly from the longitudinal axis. The step portion has an annular convex portion joined to an annular concave portion and displaces at least a portion of the center panel vertically in a direction parallel to the longitudinal axis. The curl defines an outer perimeter of the end member. The circumferential chuck wall extends downwardly from the curl to the transition wall. The transition wall connects the chuck wall with the peripheral edge of the center panel. The transition wall has a folded portion extending outwardly relative to the longitudinal axis.
摘要翻译： 罐端部件具有中心板，圆周卡盘壁和过渡壁。 中心面板围绕纵向轴线居中并具有周边边缘。 中心面板还具有从纵向轴线径向向外定位的台阶部分。 台阶部分具有连接到环形凹部的环形凸部，并且在平行于纵向轴线的方向上垂直移动中心面板的至少一部分。 卷曲限定了端部构件的外周。 圆周卡盘壁从卷曲向下延伸到过渡壁。 过渡壁将卡盘壁与中心面板的周边边缘连接。 过渡壁具有相对于纵向轴线向外延伸的折叠部分。
-
公开(公告)号：US20060293136A1
公开(公告)日：2006-12-28
申请号：US11168769
申请日：2005-06-28
申请人： George Markley , John Crocket , Timothy Turner
发明人： George Markley , John Crocket , Timothy Turner
CPC分类号： F16H7/18 , F16H7/08 , F16H2007/0804 , F16H2007/0872 , F16H2007/0874
摘要： A tensioner for imparting tension to a chain having a body, a resilient chain guide element, at least one blade spring, and at least one bracket. The body of the tensioner has a surface with a profile of the path of a new chain and a groove found longitudinally along the length of the surface. The resilient chain guide element, on the surface of the body has a chain contact surface and two ends wrapped around the ends of the body, with the chain guide being sufficiently larger than the body, such that the chain contact surface is capable of being biased away from the body. The blade spring is present in the groove with its end in the containments means of the groove, biasing the chain guide out and away from the body.
摘要翻译： 一种张紧器，用于向具有主体的链条，弹性链条引导元件，至少一个刀片弹簧和至少一个支架施加张力。 张紧器的主体具有表面，其具有沿着表面的长度纵向发现的新链条和凹槽的路径的轮廓。 主体表面上的弹性链条引导元件具有链接表面，并且包裹在主体端部的两个端部，链条引导件足够大于主体，使得链接表面能够被偏置 远离身体。 刀片弹簧存在于凹槽中，其端部位于槽的容纳装置中，将链条引导件偏压和远离主体。
-
公开(公告)号：US20060186127A1
公开(公告)日：2006-08-24
申请号：US11063430
申请日：2005-02-22
CPC分类号： B21D51/30 , B65B7/2857 , B65B7/2878
摘要： A can end and can body are seamed to each other using a seaming roller, seaming chuck and a laser fusing the peripheral portion of the can end to the can body. Laser seaming allows less metal to be used in the can end and can body. The can end and can body seam is further reinforced in order to ensure that the can is capable of withstanding internal pressures. The reinforcing techniques include crimping the seam with one or more crimping rollers, reforming the seam so as to incline the seam towards a central axis extending through the center of the can end and can body, and using multiple laser welds spaced apart from each other in the vicinity of the seam.
摘要翻译： 使用接缝辊，接缝卡盘和将罐端部的周边部分熔合到罐体的激光器将罐端部和罐体彼此缝合。 激光缝合允许在罐头和罐体中使用较少的金属。 罐体端部和罐体接缝进一步加强，以确保罐体能够承受内部压力。 加强技术包括用一个或多个压接辊压接接缝，重新形成接缝，以使接缝朝向延伸穿过罐端和罐体中心的中心轴线倾斜，并且使用彼此间隔开的多个激光焊缝 接缝附近。
-
公开(公告)号：US07000797B2
公开(公告)日：2006-02-21
申请号：US10317636
申请日：2002-12-12
申请人： Randy G. Forrest , Timothy Turner
发明人： Randy G. Forrest , Timothy Turner
IPC分类号： B65D17/34
CPC分类号： B65D17/08 , B65D7/36 , B65D17/4012 , B65D2517/0014 , B65D2517/0062 , B65D2517/007 , B65D2517/0076 , Y10S220/906
摘要： An end member for a container having a circumferential sidewall, the end member having a peripheral seaming edge adapted to be integrally connected to the sidewall, and having a central panel wall with a means for opening a frangible panel segment of the panel wall is claimed. The end member comprises a deboss panel recessed in the central panel. The deboss panel has first and second spaced apart end portions joined by first and second sidewalls. The first spaced apart end portion has an apex and first and second arcuate portions. A distance between the first and second arcuate portions is defined by a plurality of progressively increasing secant lengths located in spaced relation from the apex. A score groove is located within the deboss panel defining an outer perimeter of the frangible panel segment. The score groove has a first end and a second end joined to the first end by a curvilinear segment. The first end and the second end are separated by a generally linear hinge segment of the central panel wall. The curvilinear segment includes first and second curved segments joined by a transition point located adjacent the apex of the deboss panel. The generally arcuate transition region is defined by a plurality of progressively increasing chordal lengths located in spaced relation from the apex of the deboss panel. A ratio of the plurality of progressively increasing secant lengths to the progressively increasing chordal lengths increases along respective lengths of the first and second arcuate portions of the deboss panel.
-
公开(公告)号：US20140302515A1
公开(公告)日：2014-10-09
申请号：US13571106
申请日：2012-08-09
IPC分类号： G01N33/574 , A61N5/10
CPC分类号： G01N33/57434 , A61N5/10 , C12Q1/6886 , C12Q2600/112 , C12Q2600/158 , G01N33/57415 , G01N2800/50
摘要： Kaiso, a transcriptional regulator with bimodal DNA-binding specificity, is over-expressed in breast cancer cells, and its nuclear localization is correlated with malignant and lymph node metastasis. Depleted expression of Kaiso in those cells results in a significant decrease in basal and EGF-induced cell migration, and this is associated with increased E-cadherin expression. The data reported and described herein provide significant evidence that Kaiso is involved in breast cancer invasion and metastasis. Kaiso nuclear localization is a biomarker that is associated with invasive and metastatic infiltrating ductal breast cancer that may be used to monitor, detect, and/or track the progress of disease in a patient.
摘要翻译： Kaiso是具有双峰DNA结合特异性的转录调节因子，在乳腺癌细胞中过表达，其核定位与恶性淋巴结转移相关。 在这些细胞中Kaiso的消耗表达导致基础和EGF诱导的细胞迁移显着降低，并且这与E-钙粘蛋白表达增加相关。 本文报道和描述的数据提供了Kaiso参与乳腺癌侵袭和转移的重要证据。 凯索核定位是与侵入性和转移性浸润性导管乳腺癌相关的生物标志物，其可用于监测，检测和/或跟踪患者疾病进展。
-
公开(公告)号：US07644833B2
公开(公告)日：2010-01-12
申请号：US11235653
申请日：2005-09-26
CPC分类号： B65D17/502 , B65D17/08 , B65D17/4012 , B65D2517/0007 , B65D2517/0011 , B65D2517/0061 , B65D2517/0062 , B65D2517/0076 , B65D2517/0079 , B65D2517/0082
摘要： A can end member for a beverage container is disclosed. The end member has a curl at least substantially defining a perimeter of the can end, a chuck wall extending downwardly and radially inwardly from the curl, and a central panel wall centered about a longitudinal axis. The central panel wall has a product side and a public side. The public side has a means for opening a frangible panel segment. The end member also has a fold joining the chuck wall with the central panel wall. The fold has an opening. A fluid is located adjacent the opening.
摘要翻译： 公开了用于饮料容器的罐端部件。 端部构件具有至少基本上限定罐端部的周边的卷曲，从卷曲向下并径向向内延伸的卡盘壁和围绕纵向轴线居中的中心壁板。 中央面板墙具有产品侧和公共侧。 公众方面有一个方法来打开一个脆弱的小组部分。 端部构件还具有将卡盘壁与中心面板壁连接的折叠。 折叠有一个开口。 流体位于开口附近。
-
-
-
-
-
-
-
-
-
搜索结果
37 条记录 (耗时 0.032 秒)
